Psoriasis: Compliance and calcipotriol + betamethazone dipropionate

Kochergin N.G.

doi:https://doi.org/

Kochergin N.G.

I.M. Sechenov Moscow Medical Academy

Psoriasis: Compliance and calcipotriol + betamethazone dipropionate

Authors:

Kochergin N.G.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2010;8(3): 42‑46

Read: 2418 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kochergin NG. Psoriasis: Compliance and calcipotriol + betamethazone dipropionate. Russian Journal of Clinical Dermatology and Venereology. 2010;8(3):42‑46. (In Russ.)

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)

Использование инфографики авторами научных работ

References:

Horn E. NPF USA 2007.
Winterfield L.S. et al. Psoriasis treatment: current and emerging directed therapies. Ann Reum Dis 2005; 64 (Suppl II): 87-90.
Feldman S.R. et al. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol 2008; 59: 6: 1009-1016.
Brown K., Rehmus W., Kimball A. J Am Acad Dermatol 2006; 55: 607-613.
Ruzicka T., Lorenz B. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks' treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. Br J Dermatol 1998; 138: 254-258.
Kaufmann R. et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris.Dermatology 2002; 205: 389-393.
Kragballe K. et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2006; 155: 737-741.
Filimonkova N.N. i dr. Klinicheskii effekt posledovatel'nogo naznacheniya preparatov daivobet i daivoneks v kompleksnoi terapii bol'nykh psoriazom. Vestn dermatol venerol 2006; 6: 35-41.
Korotkii N.G. i dr. Daivobet - novyi vysokoeffektivnyi preparat dlya naruzhnogo lecheniya bol'nykh srednetyazhelym i tyazhelym vul'garnym psoriazom. Klin dermatol venerol 2007; 4: 64-69.
Monakhov K.N. i dr. Sovremennye aspekty naruzhnoi terapii psoriaza. Klin dermatol venerol 2006; 2: 47-50.
Togoeva L.Sh. i dr. Naruzhnaya terapiya ogranichennykh form psoriaza. Klin dermatol venerol 2008; 2: 42-44.
Katsambas A. et al. Improvement in quality of life in patients treated with adalimumab plus adjunctive topical therapy (calcipotriol/betamethasone) for moderate to severe psoriasis: Results of the BELIEVE study. 18th EADV Congress 2009; 1169.
Thaci D., Ortonne J.P., Chimenti S. et al. A Phase IIIb, Multi-Centre, Randomized, Double-Blind, Vehicle-Controlled Study of the Efficacy and Safety of Adalimumab With and Without Calcipotriol/Betamethasone Topical Treatment in Patients with Moderate to Severe Psoriasis: The BELIEVE Study. Br J Dermatol 2010 Apr 2. [Epub ahead of print].